Xiao Y J, Dong X, Yang H Z, Tan H Y, Zhou R L, Chen Y, Shen X B, Yan M Y
Department of Respiratory Disease and Intensive Care, Changsha Central Hospital, Changsha 410001, China.
Department of North 6, Jinyintan Hospital, Wuhan 430000, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Apr 12;44(4):354-359. doi: 10.3760/cma.j.cn112147-20200707-00785.
To describe the epidemiological characteristics and clinical features of patients with fatal coronavirus disease (COVID-19), in order to provide evidence for clinical diagnosis and treatment. In this retrospective study, we analyzed data on 141 fatal cases of confirmed COVID-19 that occurred among patients in Jinyintan Hospital in Wuhan, China, from January 20 to March 6, 2020. We analyzed their epidemiological characteristics, clinical and radiological features, laboratory results, and treatment. Of the 141 patients (49 females, 92 males), the median age was 77 years (range: 24-92 years). The most likely source of exposure included the Huanan seafood market (3, 2%), family members (6, 4%), and hospital-acquired infection (8, 6%). The remaining 116 patients (72%) had no known source of exposure. Of the patients, 101 (72%) had chronic diseases. The most common comorbidities were hypertension, diabetes and coronary heart disease. The most common clinical manifestations were fever (121, 85%), dry cough (77, 54%), shortness of breath (23, 16%), and chest pain (15, 10%). Less common clinical manifestations included fatigue (7, 4%), headache (3, 2%), disorders of consciousness (2, 1%), diarrhea (2, 1%) and lumbago (1, 0.7%). In terms of laboratory tests, the absolute value of lymphocytes in most patients was reduced (132, 94%), but C-reactive protein (141, 100%), procalcitonin(121, 89%), serum amyloid (140, 99%) were significantly increased. The most common findings on imaging of the lungs were bilateral multiple mottling and ground-glass opacity (101, 72%), mainly in the lower lobes (15, 10%), with lesions being more common on the right. Other imaging findings included diffuse consolidation (4, 3%), ground-glass opacity and consolidation (20, 14%), and pneumothorax (1, 0.7%). All patients were treated with antibiotics and antiviral drugs. Other treatments included immunoglobulin (49, 35%), corticosteroids (45, 32%), continuous renal replacement therapy (24, 17%), and extracorporeal membrane oxygenation (12, 9%). All patients were treated with oxygen therapy. The mode of administration included invasive mechanical ventilation (61, 43%), noninvasive mechanical ventilation (65, 46%), and nasal catheter oxygen inhalation (15, 11%). The direct causes of death were acute respiratory distress syndrome (90, 64%), multiple organ failure (24, 17%), sudden cardiac arrest (11, 8%), viral myocarditis (8, 5%), acute myocardial infarction (4, 3%), cerebrovascular accident (3, 2%), and acute gastrointestinal bleeding (1, 0.7%). Risk factors for death due to COVID-19 included older age, male sex, and the presence of comorbidities. The most common direct causes of death were acute respiratory distress syndrome, multiple organ failure, sudden cardiac arrest, and viral myocarditis.
描述新型冠状病毒肺炎(COVID-19)死亡患者的流行病学特征和临床特点,为临床诊断与治疗提供依据。在这项回顾性研究中,我们分析了2020年1月20日至3月6日在中国武汉金银潭医院确诊的141例COVID-19死亡病例的数据。我们分析了他们的流行病学特征、临床和影像学特征、实验室检查结果及治疗情况。141例患者中(女性49例,男性92例),年龄中位数为77岁(范围:24 - 92岁)。最可能的暴露源包括华南海鲜市场(3例,2%)、家庭成员(6例,4%)和医院获得性感染(8例,6%)。其余116例患者(72%)无明确暴露源。患者中,101例(72%)患有慢性病。最常见的合并症为高血压、糖尿病和冠心病。最常见的临床表现为发热(121例,85%)、干咳(77例,54%)、气短(23例,16%)和胸痛(15例,10%)。较少见的临床表现包括乏力(7例,4%)、头痛(3例,2%)、意识障碍(2例,1%)、腹泻(2例,1%)和腰痛(1例,0.7%)。实验室检查方面,多数患者淋巴细胞绝对值降低(132例,94%),但C反应蛋白(141例,100%)、降钙素原(121例,89%)、血清淀粉样蛋白(140例,99%)显著升高。肺部影像学最常见表现为双侧多发斑片影和磨玻璃影(101例,72%),主要位于下叶(15例,10%),右侧病变更常见。其他影像学表现包括弥漫性实变(4例,3%)、磨玻璃影和实变(20例,14%)和气胸(1例,0.7%)。所有患者均接受了抗生素和抗病毒药物治疗。其他治疗包括免疫球蛋白(49例,35%)、糖皮质激素(45例,32%)、连续性肾脏替代治疗(24例,17%)和体外膜肺氧合(12例,9%)。所有患者均接受了氧疗。给药方式包括有创机械通气(61例,43%)、无创机械通气(65例,4 %)和鼻导管吸氧(15例,11%)。直接死亡原因包括急性呼吸窘迫综合征(90例,64%)、多器官功能衰竭(24例,17%)、心搏骤停(11例, 8%)、病毒性心肌炎(8例,5%)、急性心肌梗死(4例,3%)、脑血管意外(3例,2%)和急性消化道出血(1例,0.7%)。COVID-19死亡的危险因素包括高龄、男性及合并症。最常见的直接死亡原因是急性呼吸窘迫综合征、多器官功能衰竭、心搏骤停和病毒性心肌炎。
Zhonghua Jie He He Hu Xi Za Zhi. 2021-4-12
Am J Respir Crit Care Med. 2020-6-1
Chin Med J (Engl). 2020-5-5
Ann Palliat Med. 2020-7
Chest. 2022-8